1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Calliditas Therapeutics AB (publ)
  6. Summary
    CALTX   SE0010441584

CALLIDITAS THERAPEUTICS AB (PUBL)

(CALTX)
  Report
Real-time Estimate Cboe Europe  -  07:18 2022-07-06 am EDT
97.93 SEK   +2.86%
07/01Calliditas Therapeutics AB - Number of shares and votes in Calliditas Therapeutics
AQ
06/30Number of shares and votes in Calliditas Therapeutics
AQ
06/29Calliditas Therapeutics Signs Deal With Jefferies for Potential Sale of Up to $75 Million of American Depositary Shares
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
06/30/2022 07/01/2022 07/04/2022 07/05/2022 07/06/2022 Date
92.35(c) 96.3(c) 96.05(c) 95.2(c) 96.75 Last
96 809 170 763 123 726 159 175 88 845 Volume
+1.99% +4.28% -0.26% -0.88% +1.63% Change
More quotes
Estimated financial data (e)
Sales 2022 605 M 57,4 M 57,4 M
Net income 2022 -536 M -50,9 M -50,9 M
Net cash position 2022 323 M 30,6 M 30,6 M
P/E ratio 2022 -10,0x
Yield 2022 -
Sales 2023 2 313 M 219 M 219 M
Net income 2023 954 M 90,5 M 90,5 M
Net cash position 2023 740 M 70,3 M 70,3 M
P/E ratio 2023 7,05x
Yield 2023 -
Capitalization 5 627 M 534 M 534 M
EV / Sales 2022 8,77x
EV / Sales 2023 2,11x
Nbr of Employees 71
Free-Float 81,7%
More Financials
Company
Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug... 
Sector
Pharmaceuticals
Calendar
08/18Earnings Release
More about the company
Ratings of Calliditas Therapeutics AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about CALLIDITAS THERAPEUTICS AB (PUBL)
07/01Calliditas Therapeutics AB - Number of shares and votes in Calliditas Therapeutics
AQ
06/30Number of shares and votes in Calliditas Therapeutics
AQ
06/29Calliditas Therapeutics Signs Deal With Jefferies for Potential Sale of Up to $75 Milli..
MT
06/29Calliditas Therapeutics Seeks Approval For $75 Million At-the-market Framework In US
MT
06/28CALLIDITAS THERAPEUTICS : establishes a U.S. At-the-Market Program
PU
06/21CALLIDITAS THERAPEUTICS : Issuance and repurchase of C-shares to establish an at-the-marke..
PU
06/21Calliditas Therapeutics Plans Share Offering, Repurchase For At-the-market Program
MT
06/20Issuance and repurchase of C-shares to establish an at-the-market program
AQ
05/20CALLIDITAS THERAPEUTICS : INTERIM REPORT JANUARY 1ST – MARCH 31ST 2022 - Form 6-K
PU
05/19SECTOR UPDATE : Health Care Stocks Edging Higher Near Thursday Close
MT
05/19SECTOR UPDATE : Health Care Stocks Edging Lower in Thursday Trading
MT
05/19Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
AQ
05/19Calliditas Therapeutics AB Announces Board Changes
CI
05/19Calliditas Therapeutics Receives Positive European Medicines Agency Opinion for Kidney ..
MT
05/19Calliditas Therapeutics Up 13% After European Medicines Agency Committee Gives Positive..
MT
More news
News in other languages on CALLIDITAS THERAPEUTICS AB (PUBL)
06/29Calliditas Therapeutics signe un accord avec Jefferies pour la vente potentielle d'un m..
06/29Calliditas Therapeutics demande l'approbation d'un cadre de 75 millions de dollars sur ..
06/21Calliditas Therapeutics prévoit d'offrir et de racheter des actions dans le cadre d'un ..
06/16OPINIONES DE LOS ANALISTAS DEL DÍA : H&M, LSE, Ubisoft, Akzo Nobel, ASOS, Belimo, Deutsche..
06/16Des banques centrales partout
More news
Analyst Recommendations on CALLIDITAS THERAPEUTICS AB (PUBL)
More recommendations
Chart CALLIDITAS THERAPEUTICS AB (PUBL)
Duration : Period :
Calliditas Therapeutics AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CALLIDITAS THERAPEUTICS AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 95,20 SEK
Average target price 241,67 SEK
Spread / Average Target 154%
EPS Revisions
Managers and Directors
Renée Julie Elisabet Aguiar-Lucander Chief Executive Officer
Fredrik Johansson Chief Financial Officer
Elmar J. Schnee Chairman
Johan Erik Häggblad Chief Scientific Officer
Richard Philipson Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CALLIDITAS THERAPEUTICS AB (PUBL)-15.60%534
MERCK KGAA-26.06%74 764
KYOWA KIRIN CO. LTD.-0.64%12 330
SK BIOPHARMACEUTICALS CO., LTD.-19.75%4 650
BETTA PHARMACEUTICALS CO., LTD.-27.13%3 596
YUHAN CORPORATION-7.09%2 987